DC47681 |
PNU-EDA-Gly5
|
PNU-EDA-Gly5 is an oligo-glycine linker-payload for ADC synthesis, composed of a DNA topoisomerase I inhibitor PNU-159682 and a linker EDA-Gly5. |
DC47680 |
PSMA-Val-Cit-PAB-MMAE
|
PSMA-Val-Cit-PAB-MMAE is a novel small-molecule PSMA-targeted conjugate based on the monomethyl auristatin E for the chemotherapy of prostate cancer. |
DC47148 |
Mal-(CH2)5-Val-Cit-PAB-Eribulin
|
Mal-(CH2)5-Val-Cit-PAB-Eribulin is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal-(CH2)5-Val-Cit-PAB. |
DC46407 |
Desmethyl Vc-seco-DUBA
|
Desmethyl Vc-seco-DUBA consists a cleavable ADC linker (Desmethyl Vc-seco) and a DNA alkylating agent (DUBA). Desmethyl Vc-seco-DUBA can be used in the synthesis of antibody-drug conjugates (ADCs). |
DC46251 |
Azide-PEG4-VC-PAB-Doxorubicin
|
Azide-PEG4-VC-PAB-Doxorubicin is a drug-linker conjugate composed of a cytotoxic anthracycline antibiotic Doxorubicin and a linker Azide-PEG4-VC-PAB to make antibody drug conjugate (ADC). |
DC46238 |
MC-Val-Cit-PAB-dimethylDNA31
|
MC-Val-Cit-PAB-dimethylDNA31 is a drug-linker conjugate for ADC with potent antitumor activity by using dimethylDNA31, linked via the ADC linker MC-Val-Cit-PAB. DimethylDNA31 has effective bactericidal activity against persisters and stationary-phase S. aureus. |
DC46213 |
OSu-PEG4-VC-PAB-Duocarmycin SA
|
SA is a drug-linker conjugate for ADC with potent antitumor activity by using Duocarmycin SA (a potent DNA alkylation activator), linked via the cleavable ADC linker OSu-PEG4-VC-PAB. |
DC46212 |
MAC-VC-PABC-ST7612AA1
|
MAC-VC-PABC-ST7612AA1 is a part of antibody drug conjugates (ADCs) charged with HDAC inhibitor by a linker, shows antitumor activity. |
DC46211 |
FCHFHS-ST7612AA1
|
FCHFHS-ST7612AA1 is a part of antibody drug conjugates (ADCs) charged with HDAC inhibitor by a linker, shows antitumor activity. |
DC46204 |
N3-PEG8-Phe-Lys-PABC-Gefitinib
|
N3-PEG8-Phe-Lys-PABC-Gefitinib is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC. |